Canada· CA-DIN-02446901
ZERBAXA
A ceftolozan und beta-lactamase-inhibitor product containing tazobactam (tazobactam sodium) + ceftolozane (ceftolozane sulfate), registered in Canada by MERCK CANADA INC. The same ATC class is registered in 11 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Ceftolozan und beta-lactamase-inhibitor is registered in 11 of 19 countries.
Countries holding a registration under ATC J01DI54 (ceftolozan und beta-lactamase-inhibitor), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 7 of them publish a price we can compare per daily dose
Ceftolozan und beta-lactamase-inhibitor · ATC J01DI54
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- TAZOBACTAM (TAZOBACTAM SODIUM) + CEFTOLOZANE (CEFTOLOZANE SULFATE)
- Manufacturer
- MERCK CANADA INC
- Country
- Canada (CA)
- ATC code
- J01DI54
- ATC class
- Ceftolozan und Beta-Lactamase-Inhibitor
- Defined daily dose
- 3 g, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ceftolozan und beta-lactamase-inhibitor in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandZerbaxa 1.5 g, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungMSD Merck Sharp & Dohme AG
- CzechiaZERBAXAMerck Sharp & Dohme B.V., Haarlem
- SpainZERBAXA 1 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandZerbaxaMerck Sharp & Dohme B.V.
- FranceZERBAXA 1 g/0,5 g, poudre pour solution à diluer pour perfusionMERCK SHARP & DOHME (PAYS-BAS)
- United KingdomZerbaxa 1g/0.5g powder for concentrate for solution for infusion vialsMerck Sharp & Dohme (UK) Ltd
- IrelandZerbaxa 1 g/0.5 g powder for concentrate for solution for infusionMerck Sharp & Dohme BV,
- IcelandZerbaxaMerck Sharp & Dohme B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zerbaxa
- Liechtenstein · Zerbaxa
- Norway · Zerbaxa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/43044a86-9007-4bc8-9d87-299e91436d08 GET /v1/drugs/43044a86-9007-4bc8-9d87-299e91436d08?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02446901",
"form": "POWDER FOR SOLUTION",
"class": "Human",
"routes": [
"INTRAVENOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "J01DI54",
"schedule": [
"Prescription"
],
"drug_code": "93248",
"strengths": [
"0.5 G",
"1 G"
],
"ahfs_class": null,
"substances": [
"TAZOBACTAM (TAZOBACTAM SODIUM)",
"CEFTOLOZANE (CEFTOLOZANE SULFATE)"
],
"product_categorization": null
}See everything about ceftolozan und beta-lactamase-inhibitor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.